Real-world study questions survival benefit of triple therapy in patients with COPD

Over a 5-year observation period, patients with chronic obstructive pulmonary disease (COPD) who received triple therapy did not experience a survival benefit when compared to those who did not receive this treatment in real-world practice, according to a study.

Among the 19,358 patients aged ≥40 years included in the study, those who received triple therapy exhibited higher prevalence rates of comorbidities such as lung cancer, thoracic malignancies, bronchiectasis, and heart failure compared to the group that did not receive triple therapy.

The risk of mortality was found to be significantly higher among patients on triple therapy than in those who were not, even after adjusting for age, sex, and COPD exacerbations.

Reference
Liao KM, Wang JJ, Ho CH. Real-World Experience of Treating Chronic Obstructive Pulmonary Disease with Triple Therapy. Int J Chron Obstruct Pulmon Dis. 2023;18:1057-1066. doi: 10.2147/COPD.S404039. PMID: 37309394; PMCID: PMC10257929.